Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
In a recent transaction, Jerrold B. Grossman, a director at ADMA Biologics, Inc. (NASDAQ:ADMA), sold 10,000 shares of common stock. The shares were sold at a weighted average price of $21.31, amounting to a total of $213,100. The sale was conducted on June 9, 2025. The transaction comes as ADMA shows remarkable strength, with the stock delivering nearly 99% returns over the past year and maintaining an "EXCELLENT" financial health rating according to InvestingPro analysis.
In addition to the sale, Grossman exercised stock options to acquire 10,000 shares at a price of $5.00 each, totaling $50,000. Following these transactions, Grossman holds 478,194 shares directly. The transactions were reported in a Form 4 filing with the Securities and Exchange Commission. With a current market capitalization of $5 billion and trading above its Fair Value, ADMA has caught analysts’ attention. InvestingPro subscribers can access 11 additional key insights and a comprehensive Pro Research Report about ADMA’s future prospects.
Grossman also has indirect ownership in additional shares through various entities, including Brookwood LLC, the Jerrold Grossman 2019 Irrevocable Trust, Genesis Foundation Inc., and shares owned by his wife.
In other recent news, ADMA Biologics reported its Q1 2025 earnings with revenue surpassing forecasts, reaching $114.8 million, marking a 40% year-over-year increase. The company also highlighted an adjusted EBITDA of $47.9 million, reflecting an 81% growth compared to the previous year. ADMA Biologics projects its 2025 revenue to exceed $500 million, with plans to reach $625 million by 2026. In addition, the company received FDA approval for a new production process that is expected to enhance output efficiency. ADMA Biologics held its 2025 Annual Meeting of Stockholders, where two directors were elected, and KPMG LLP was ratified as the independent accounting firm. The company also approved executive compensation and decided on an annual advisory vote for future compensation. These developments indicate ADMA Biologics’ strategic growth and operational advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.